Halaman 5 - Kemoterapi Dokter Terbaik - TOP-152 dokter

Forbes menobatkan Dr. Tabernero sebagai salah satu dari 5 pemimpin kanker paling berpengaruh di Spanyol. Mantan Presiden European Society for Medical Oncology (Perhimpunan Onkologi Medis Eropa).

• Direktur Institut Onkologi Vall d’Hebrón
• Berspesialisasi dalam terapi target molekuler dan pengobatan kanker yang dipersonalisasi
• Penulis lebih dari 70 makalah tentang pengobatan kanker yang inovatif
• Melakukan uji klinis untuk terapi kanker usus besar yang baru

Dr. Alemdar berspesialisasi dalam onkologi medis dengan pelatihan ekstensif di Universitas Akdeniz – institusi terkemuka di Turki.

• Bersertifikat dewan dalam onkologi medis sejak 2018
• Lebih dari 15 tahun pengalaman dalam penyakit dalam dan onkologi
• Bekerja di Kompleks Rumah Sakit Medical Park Antalya
• Anggota Asosiasi Medis Turki

Profesor Madya Tarik Salman berspesialisasi dalam perawatan kanker yang dipersonalisasi di Rumah Sakit Internasional Medicalpoint, termasuk pemeriksaan profil genetik yang komprehensif.

• Lebih dari 15 tahun pengalaman dalam onkologi medis
• Pelatihan di Memorial Sloan Kettering Cancer Center
• Anggota dewan dari berbagai asosiasi onkologi
• Ahli dalam terapi target dan imunoterapi

Assoc. Prof. Ayşe İrem Yasin, M.D., is a medical oncologist who specializes in solid tumors. Her clinical focus includes breast, lung, gastrointestinal, gynecologic, and urologic cancers. She also treats brain and other CNS tumors, soft tissue sarcomas, head and neck cancers, adenocarcinomas, melanoma, Merkel cell carcinoma, and cancers of unknown primary. She practices at Medipol Acıbadem District Hospital (2025–present). She previously worked at Şişli Etfal Training and Research Hospital (2023–2025).

She completed a Medical Oncology fellowship at Bezmialem Vakıf University (2019–2022). This followed an Internal Medicine residency at the same institution (2012–2016). Her international experience includes the Breast Cancer Unit at the University of Piemonte Orientale in Novara (2022). She also trained at Basel University Hospital, Cleveland Clinic, and Harvard Medical School. She holds the ESMO Board Certificate (2022).

Assoc. Prof. Dr. Mehmet Salih İyikesici is a medical oncologist. He provides personalized care for breast, lung, and gastrointestinal cancers. He combines metabolically supported therapies with chemotherapy. His interests include the ketogenic diet in cancer care, hyperthermia, and hyperbaric oxygen therapy.

He has conducted and contributed to national and international scientific studies. Selected national peer-reviewed publications include Metabolic Supported Chemotherapy in Rectal Cancer (2020), NSCLC Patient Outcomes – Marmara University (2004), and Early-Stage Breast Cancer Outcomes (2004).

Prof. Avichai Shimoni, MD, is Director of Bone Marrow Transplantation at Sheba Medical Center. He is a hemato-oncologist with over 30 years of experience in bone marrow transplantation, cellular therapies, and advanced blood cancer care.

He leads a high-volume program for complex, high-risk blood cancers. He performs allogeneic and autologous transplants. He also provides CAR T-cell therapy for leukemia, lymphoma, and multiple myeloma. He completed a bone marrow transplantation fellowship at MD Anderson Cancer Center.

He is Chairman of Hematology at Tel Aviv University and a Professor of Hematology. He has authored more than 250 scientific papers. His research focuses on CAR T-cell therapy and stem cell transplantation. He is often listed among Israel's Best Doctors (Forbes 2025 and 2026).

Dr. Lucía González Cortijo is a medical oncologist with more than 20 years of experience. She has led the Medical Oncology Department at Hospital Universitario Quirónsalud Madrid since 2020. Her focus areas include breast and gynecologic cancers. She also works in precision oncology, targeted therapies, and immunotherapy.

She has been Principal Investigator in more than 20 Phase II–III clinical trials. She has also served as sub-investigator in over 50 international trials. She previously worked at Quirónsalud Madrid from 2009 to 2020. Before that, she was at MD Anderson Cancer Center Madrid from 2002 to 2009.

She holds an MD and a PhD (cum laude) from the Autonomous University of Madrid. She completed her Medical Oncology specialty training at Hospital 12 de Octubre. She also earned a Master’s in Molecular Oncology. She is a member of SEOM, ESMO, ASCO, and GEICAM. She is a university lecturer.

Prof. Ben Boursi is a physician in the Gastrointestinal Cancer Department at Sheba Medical Center. He specializes in internal medicine, medical oncology, and cancer epidemiology. He is board certified in internal medicine and medical oncology. He earned a B.Med.Sc (summa cum laude) and an MD (magna cum laude) from Tel Aviv University.

He completed clinical and research fellowships in GI oncology and cancer epidemiology at the University of Pennsylvania. He also completed electives at MD Anderson and Mayo Clinic. He founded the ECOG-ACRIN Microbiome Working Group. His microbiome-oncology research has been published in leading journals, including Science, and highlighted by ASCO.

He developed predictive models for early diagnosis of colorectal and pancreatic cancers. These models are now in clinical evaluation. He holds an academic appointment at Tel Aviv University. He is also an Associate Scholar at the University of Pennsylvania.

Dr. Abraham Avigdor, MD, is Director of the Institute of Hematology and Co‑Director of the Hematology & Bone Marrow Transplantation Division at Sheba Medical Center. He is an international leader in lymphoma, CAR‑T, and advanced hemato‑oncology with more than 35 years of experience. His clinical focus includes lymphomas, multiple myeloma, and complex blood cancers.

He is a pioneer in CAR‑T integration. He leads cellular therapy and bone marrow transplantation programs (autologous and allogeneic). He also advances stem cell therapies and precision diagnostics, including PET/CT‑based prognostics. His work includes immunotherapy and targeted regimens and the development of innovative, data‑driven protocols.

He collaborates with LYSA, EMCL, and international PET groups. He has authored more than 130 publications. Key roles include Founder and President of the Israeli Lymphoma Working Group, former Chair of the Israeli Lymphoma Study Group, and Senior Lecturer at Tel Aviv University. Education: MD, Ben‑Gurion University; residency, Sheba Medical Center; postdoctoral fellowship, Weizmann Institute. Awards include the Knesset Prize, the Israeli Ministry of Health Award, and the Sackler Prize.

Profesor Madya Muhammed Mustafa Atci memimpin program Onkologi Medis di Rumah Sakit Liv Universitas İstinye Topkapı, dengan penelitian ekstensif mengenai hasil kemoterapi.

• Berspesialisasi dalam onkologi medis dengan fokus pada protokol kemoterapi
• Menerbitkan berbagai studi tentang efikasi kemoterapi di jurnal-jurnal yang ditinjau oleh rekan sejawat (peer-reviewed)
• Anggota American Society of Clinical Oncology (ASCO)
• Koordinator Pendidikan untuk Sub-Cabang Onkologi Medis

Professor Raanan Berger, MD PhD, is a medical oncologist and radiotherapist. He is Director of the Cancer Center at Sheba Medical Center and heads its clinical research unit. He was listed in Forbes Israel’s “Best Doctors” (2025). He leads the genitourinary oncology program with a focus on prostate cancer. His care includes systemic therapy and radiotherapy in a multidisciplinary, patient-centered model.

He is board-certified in oncology. He earned his MD and PhD at Tel Aviv University and completed his clinical training at Sheba. He then completed a postdoctoral fellowship at Dana-Farber/Harvard, focusing on prostate cancer with Dr. Philip Kantoff and molecular oncology in Dr. William C. Hahn’s lab. He is a member of ESMO and ASCO. He has co-authored more than 20 peer-reviewed papers, including studies on outcomes in high- versus very high-risk prostate cancer and on BRCA1/2 in large cohorts.

Direktur Klinis Unit Payudara Multidisiplin dengan 322 publikasi peer-review – Dr. Kuemmel memimpin penelitian kanker payudara di Kliniken Essen-Mitte.

• Anggota Dewan Eksekutif AGO (Arbeitsgemeinschaft Gynäkologische Onkologie)
• Anggota Fakultas ESMO untuk Kanker Payudara
• PI Global dan kepala 27 investigasi dan uji klinis
• Anggota dari berbagai perkumpulan onkologi bergengsi termasuk ESMO dan ASCO

Professor Jair Bar, MD, PhD, is a thoracic oncologist and Deputy Director of the Cancer Center at Sheba Medical Center. He leads the Thoracic Oncology Unit. He treats lung cancer, including advanced non-small cell cases. His care includes medical oncology, radiotherapy, immunotherapy, and targeted therapy.

He runs a translational research lab focused on resistance to immunotherapy. He has published on exhaled-breath cancer metabolism and on angiogenesis inhibition in lung cancer.

He has chaired the Israel Lung Cancer Group since 2003. He is a member of the Israel Society of Clinical Oncology and Radiotherapy, the American Society of Clinical Oncology, and the American Association for Cancer Research. He is board-certified in Medical Oncology and Radiotherapy Oncology. He is a Senior Lecturer at Tel Aviv University.

Dr. Hila Magen, MD, leads the Multiple Myeloma and Amyloidosis Unit at Sheba Medical Center. She is a hemato-oncologist with over 35 years of experience. She is a leading Israeli expert in multiple myeloma and plasma cell disorders.

She runs a program that provides personalized care and early access to clinical trials. This includes CAR-T therapy for high-risk and relapsed or refractory myeloma and amyloidosis. Dr. Magen is a principal investigator in point-of-care CAR-T studies. She brings new immunotherapies into routine care.

Training: Fellowships in Multiple Myeloma (UAMS) and Lymphocytic Leukemia (MD Anderson). Academic: Instructor, Tel Aviv University. Research: Author of 100+ publications, contributor to landmark myeloma studies, and reviewer for international journals.

Pakar terkemuka dalam leukemia limfositik kronis (LLK) – Profesor Bosch telah merintis pengobatan dan teknologi baru untuk penyakit hematologi.

• Melakukan lebih dari 80 uji klinis dari fase 1 hingga fase 3
• Menerbitkan lebih dari 100 artikel di jurnal medis terkemuka
• Kepala Hematologi di IOB Institute of Oncology
• Presiden kelompok Spanyol untuk studi LLK (GELLC)

Peneliti Utama dalam uji klinis untuk kanker ovarium, serviks, dan endometrium – Dr. Oaknin memimpin penelitian terobosan di Hospital Quiron Barcelona.

• Penulis 100+ publikasi tentang tumor ginekologi
• Anggota dewan eksekutif Kelompok GEICO (Kelompok Penelitian Kanker Ovarium Spanyol)
• Anggota fakultas untuk Gyn-Track di ESMO
• Perwakilan Spanyol dalam Komite Serviks Kelompok GCIG

Spesialis terkemuka Israel dalam imunoterapi kanker paru-paru – Prof. Peled mengepalai Unit Kanker Toraks di Pusat Kanker Davidoff.

• Menyelesaikan pelatihan Fellowship dalam kanker paru-paru di University of Colorado Denver
• Menerima penghargaan MERIT dari American Society of Clinical Oncology (ASCO)
• Memimpin Komite Deteksi Dini & Pencegahan IASLC
• Berspesialisasi dalam pengobatan personalisasi dan imunoonkologi untuk kanker paru-paru